MedTrace Logo

PrefeRences And ChemoTherapy In Breast Cancer patiEnts

NCT06332976 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2024-03-27

No results posted yet for this study

Summary

The aim of the present study is to ask women treated with adjuvant or neoadjuvant chemotherapy for breast cancer what survival benefit would justify the treatment.

The benefit should be evaluated in terms of Survival rate trade off and Survival time trade off value. The analyses will be conducted into three different groups of patients to value the survival benefit expected:

1. before to start the chemotherapy
2. during chemotherapy
3. after the end of chemotherapy

Conditions

  • Female Breast Cancer

Interventions

OTHER

Completion of questionnaires

Completion of questionnaires at the time of study entry

Sponsors & Collaborators

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Emilia Montagna, MD · European Institute of Oncology

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-04
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06332976 on ClinicalTrials.gov